Last €58.92 EUR
Change Today 0.00 / 0.00%
Volume 0.0
BRM On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
As of 3:34 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BRM) Snapshot

Open
€55.63
Previous Close
€58.92
Day High
€58.92
Day Low
€55.25
52 Week High
03/4/15 - €58.92
52 Week Low
06/10/14 - €34.12
Market Cap
97.9B
Average Volume 10 Days
1.4K
EPS TTM
--
Shares Outstanding
1.7B
EX-Date
04/1/15
P/E TM
--
Dividend
€1.48
Dividend Yield
1.87%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BRM)

bristol-myers squibb co (BRM) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company’s products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887

bristol-myers squibb co (BRM) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $901.1K
Chief Operating Officer and Director
Total Annual Compensation: $748.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $843.1K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $736.1K
Compensation as of Fiscal Year 2013.

bristol-myers squibb co (BRM) Key Developments

Bristbristol-Myers Squibb Company Announces Quarterly Dividend, Payable on May 1, 2015

Bristol-Myers Squibb Company announced that it will pay a quarterly dividend on its common stock of $0.37 per share on May 1 to shareholders of record on April 6.

Bristol-Myers Squibb Company Declares Quarterly Dividend, Payable on June 1, 2015

The board of directors of Bristol-Myers Squibb Company declared a quarterly dividend of $0.50 per share on the $2.00 convertible preferred stock of the company, payable on June 1, 2015 to stockholders of record at the close of business on May 8, 2015.

Bristol-Myers Squibb Company Announces U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy (ipilimumab) as Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection. The projected FDA action date is October 28, 2015. For many stage 3 melanoma patients, there is a high risk of disease recurrence and there has been a low overall survival rate. By five years, the majority of patients experience disease recurrence, with nearly 90% in those considered at the high risk. Once the disease returns, survival rates have been been very low historically, ranging from 11% to 20%. This filing acceptance is based on clinical data from a randomized, double-blind Phase III trial, CA 184-029 (EORTC 18071), assessing the efficacy of Yervoy, at the investigational dose of 10 mg/kg, in preventing or delaying recurrence after complete resection of high-risk stage 3 melanoma.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRM:GR €58.92 EUR 0.00

BRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.27 USD +0.65
Amgen Inc $159.19 USD +0.63
Biogen Idec Inc $414.13 USD +1.34
Eli Lilly & Co $70.65 USD +0.28
Novo Nordisk A/S kr315.60 DKK +0.60
View Industry Companies
 

Industry Analysis

BRM

Industry Average

Valuation BRM Industry Range
Price/Earnings 51.6x
Price/Sales 6.5x
Price/Book 6.9x
Price/Cash Flow 51.4x
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.